Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study - 06/12/24
, Mengzhao Yang a, 1, Guanyue Su a, 1, Guowu Qian b, 1, Yiqiang Yuan c, 1, Jia Yu a, Silin Li d, Changshuang Wang e, Mingxia Lu e, Hong Luo f, Shixi Zhang g, Guangming Li h, Donghua Zhang i, Ling Wang c, Guotao Li j, Xiaoli Jin j, Juan Wang h, Mingming Wang g, Ming Cheng k, Haiyu Wang a, Junbiao Chang l, ⁎ , Zujiang Yu a, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Objectives |
Azvudine has been designated as a priority treatment for patients infected with SARS-CoV-2, however, clinical evidence in hospitalized cases remains insufficient.
Methods |
We performed a multi-center, retrospective cohort study to evaluate the effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 in China (NCT06349655). Kaplan-Meier method, Cox regression model, subgroup analysis, and seven sensitive analyses were employed.
Results |
A total of 32864 hospitalized patients with SARS-CoV-2 were enrolled, in which 5735 azvudine recipients and 5735 controls were selected using 1:1 propensity score matching. Based on Kaplan-Meier analysis, azvudine significantly reduced rates of all-cause death (P < 0.0001) and composite disease progression (P = 0.00019). Cox regression analysis demonstrated that hazard ratios of all-cause death and composite disease progression were 0.68 (95%CI: 0.598–0.775, P < 0.001) and 0.88 (95% CI: 0.795–0.976, P = 0.016), respectively. Subgroup analysis showed preference of azvudine for patients receiving antibiotics in reducing all-cause death and composite disease progression. Seven sensitivity analyses verified the robustness of our results. Safety analysis on adverse events showed no significant difference between both groups.
Conclusions |
This study suggested that azvudine may reduce all-cause death and composite disease progression in hospitalized patients with SARS-CoV-2 infection without serious adverse events. However, the findings are susceptible to some potential biases, and further studies still need to identify the efficacy of azvudine.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Azvudine recipients may potentially experience a reduced mortality and composite disease progression. |
• | Azvudine exhibited acceptable safety in patients with SARS-CoV-2 infection. |
• | Azvudine may be a promising antiviral agent for treating COVID-19. |
Keywords : SARS-CoV-2, Azvudine, Real-world, All-cause death, Composite disease progression
Plan
Vol 89 - N° 6
Article 106355- décembre 2024 Retour au numéro
Article précédent
- The latform Trial n VID-19 priming and sting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old
- C. McLeod, M. Dymock, KL Flanagan, M. Plebanski, HS Marshall, MJ Estcourt, U. Wadia, MC Tjiam, CC Blyth, K. Subbarao, FL Mordant, S. Nicholson, N. Cain, R. Brizuela, SN Faust, RB Thornton, Z. Ellis, A. Mckenzie, JA Marsh, TL Snelling, PC Richmond
- The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis
- Nick King Ngai Chow, Charmaine Yuk Wah Tsang, Yan Hei Chan, Shalina Alisha Telaga, Lok Yan Andes Ng, Chit Ming Chung, Yan Ming Yip, Peter Pak-Hang Cheung
Bienvenue sur EM-consulte, la référence des professionnels de santé.